Skip to contentH
Haemonetics Corp
H
HAEHaemonetics Corp Q2 2022 · 10-Q
Revenue$239.90M$239.90M+14.5% vs Q2 2021 Net Income$14.86M$14.86M−69.1% vs Q2 2021 EPS Diluted$0.29$0.29−69.1% vs Q2 2021 Gross Profit$122,541,000+15.9% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Haemonetics Corp · CIK 313143 · Engraved from SEC EDGAR
Operating Cash Flowderived$43,460,000+49.1% Free Cash Flowderived$22,648,000+8.8% Margins · derivedGross margin51.1%+0.6 pt vs Q2 2021
Operating margin10.2%−17.8 pt vs Q2 2021
Net margin6.2%−16.8 pt vs Q2 2021
ended Oct 2, 2021 · filed Nov 9, 2021 · 38 d after period end